DSC Platform
More Than a Cell Source
DSC is Decinova’s proprietary decidua-derived stromal-cell platform. Steroid-refractory acute GVHD (SR-aGVHD) is Decinova’s priority development and partnering focus. Decinova’s DSC know-how extends beyond cell isolation — built on the biological rationale and differentiation established for the platform, with deep, hands-on experience across the full translational pathway from source tissue to clinical-ready product.
What Are DSCs
A Stromal-Cell Platform Rooted in Decidual Biology
DSCs are derived from the human decidua — a tissue specialised in regulating immune tolerance at the maternal–fetal interface. That origin gives DSCs an immunomodulatory profile distinct from conventional bone-marrow, adipose or umbilical-cord stromal-cell sources. The platform is developed as an allogeneic, cryopreserved, off-the-shelf cell product, with differentiation evaluated across tissue origin, immunomodulatory phenotype, functional activity and manufacturing process — not assumed equivalence with conventional MSC products.
Disease & Evidence Settings
Three Clinical-Development Evidence Settings
Steroid-Refractory Acute GVHD
Decinova’s priority development and partnering focus. Published long-term follow-up in 21 patients treated with DSCs for severe acute GVHD reported 81% 1-year, 67% 2-year and 57% 4-year survival (Source: Sadeghi et al., PMID: 31173898) — published clinical follow-up, not definitive evidence of efficacy.
View the Lead Program →Hemorrhagic Cystitis
A published clinical-development evidence setting exploring DSC in severe hemorrhagic cystitis, contributing to the platform’s broader translational and safety experience.
View Clinical Evidence →ARDS / Severe Inflammatory Lung Disease
An additional clinical and translational evidence setting for DSC in severe inflammatory lung disease, informing the platform’s biological and safety profile.
View Clinical Evidence →From Biology to Product
Platform Capabilities
Source & Isolation
Decidual tissue sourcing and cell-isolation strategy.
Expansion & Banking
Cell expansion, banking and scalable manufacturing concepts.
Characterization
Phenotypic and functional characterization relevant to product identity and biological activity.
Cryopreservation
Development of a cryopreserved product format supporting practical clinical use.
Preclinical Development
Biological, safety and toxicology experience supporting clinical translation.
Clinical Administration
Experience with dosing, handling, administration and clinical monitoring.
Regulatory Development
Experience generated through previous regulatory submissions and development programs across multiple jurisdictions.
Regulatory History
Historical Development Context
Historical platform-development milestones include prior clinical, regulatory and regional development experience associated with earlier licensed programs. Any historical regulatory status should be read with its original date, jurisdiction and current status, and should not be interpreted as a current marketing authorization or as Decinova holding those historical designations today.
See the Full Development & Regulatory History →Adjacent Technologies
Selected Adjacent Technologies
Alongside DSC, Decinova’s translational experience extends to selected adjacent technologies — explored for partner-specific development rather than as equally active proprietary programs: extracellular-vesicle and exosome-related development, Wharton’s Jelly stromal cells, adipose-derived stromal cells, and selected regenerative-medicine opportunities.
Explore Technology Development →Partner on the DSC Platform
We welcome licensing, co-development, regional development, manufacturing-collaboration and strategic-investment discussions on the DSC platform.